Pioneering a New World of Medicine
with Bubbles and Ultrasound
In solid tumors such as pancreatic cancer and in central nervous system disorders, biological barriers remain a major obstacle to effective drug delivery.
Wellthera has developed BUS-DDS (Bubble Ultrasound-mediated Drug Delivery System), an innovative platform that combines therapeutic microbubbles with low-intensity ultrasound.
BUS-DDS enables drugs to cross previously inaccessible biological barriers, expanding the therapeutic potential of both existing and novel medicines and creating new treatment opportunities.
Stay up to date with our latest announcements, research activities, and events.
Website Update and Publication of Policies
We are pleased to announce an update to our website. This update includes the publication of our Privacy Policy, Terms of Use, and Compliance
Notice of Director Appointments
We are pleased to announce that at our General Shareholders’ Meeting held on February 25, 2026, we amended our Articles of Incorporation to transition to
Notice of Website Update
We are pleased to announce that our corporate website has been updated. This update includes a reorganization of information related to our business activities, along
Wellthera is a spin-off from Teikyo University, developing proprietary technologies based on therapeutic microbubbles and ultrasound.
With a strong focus on clinical translation, we are building a platform that advances drug delivery and supports the development of next-generation therapies.
We welcome inquiries about collaborative research, business partnerships, and investor relations.